CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW
4.1 Overview
4.1.1 Market size and forecast
4.2 Target Identification and Screening
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.3 Target Validation and Functional Informatics
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country
4.4 Lead Identification and Candidate Optimization
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market share analysis by country
4.5 Preclinical Development
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market share analysis by country
4.6 Others
4.6.1 Key market trends, growth factors and opportunities
4.6.2 Market size and forecast, by region
4.6.3 Market share analysis by country
CHAPTER 5: DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA
5.1 Overview
5.1.1 Market size and forecast
5.2 Respiratory system
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3 Infectious disease
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country
5.4 Oncology
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market share analysis by country
5.5 Immunology
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market share analysis by country
5.6 Hematology
5.6.1 Key market trends, growth factors and opportunities
5.6.2 Market size and forecast, by region
5.6.3 Market share analysis by country
5.7 Cardiovascular
5.7.1 Key market trends, growth factors and opportunities
5.7.2 Market size and forecast, by region
5.7.3 Market share analysis by country
5.8 Central Nervous System (CNS)
5.8.1 Key market trends, growth factors and opportunities
5.8.2 Market size and forecast, by region
5.8.3 Market share analysis by country
5.9 Gastrointestinal
5.9.1 Key market trends, growth factors and opportunities
5.9.2 Market size and forecast, by region
5.9.3 Market share analysis by country
6.0 Others
6.0.1 Key market trends, growth factors and opportunities
6.0.2 Market size and forecast, by region
6.0.3 Market share analysis by country
CHAPTER 6: DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE
6.1 Overview
6.1.1 Market size and forecast
6.2 Small Molecules
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market share analysis by country
6.3 Large Molecules
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market share analysis by country
CHAPTER 7: DRUG DISCOVERY OUTSOURCING MARKET, BY END USER
7.1 Overview
7.1.1 Market size and forecast
7.2 Pharmaceutical and Biotechnology companies
7.2.1 Key market trends, growth factors and opportunities
7.2.2 Market size and forecast, by region
7.2.3 Market share analysis by country
7.3 Academic Institutes
7.3.1 Key market trends, growth factors and opportunities
7.3.2 Market size and forecast, by region
7.3.3 Market share analysis by country
7.4 Others
7.4.1 Key market trends, growth factors and opportunities
7.4.2 Market size and forecast, by region
7.4.3 Market share analysis by country
CHAPTER 8: DRUG DISCOVERY OUTSOURCING MARKET, BY REGION
8.1 Overview
8.1.1 Market size and forecast
8.2 North America
8.2.1 Key trends and opportunities
8.2.2 North America Market size and forecast, by Workflow
8.2.3 North America Market size and forecast, by Therapeutic area
8.2.4 North America Market size and forecast, by Drug Type
8.2.5 North America Market size and forecast, by End User
8.2.6 North America Market size and forecast, by country
8.2.6.1 U.S.
8.2.6.1.1 Key market trends, growth factors and opportunities
8.2.6.1.2 Market size and forecast, by Workflow
8.2.6.1.3 Market size and forecast, by Therapeutic area
8.2.6.1.4 Market size and forecast, by Drug Type
8.2.6.1.5 Market size and forecast, by End User
8.2.6.2 Canada
8.2.6.2.1 Key market trends, growth factors and opportunities
8.2.6.2.2 Market size and forecast, by Workflow
8.2.6.2.3 Market size and forecast, by Therapeutic area
8.2.6.2.4 Market size and forecast, by Drug Type
8.2.6.2.5 Market size and forecast, by End User
8.2.6.3 Mexico
8.2.6.3.1 Key market trends, growth factors and opportunities
8.2.6.3.2 Market size and forecast, by Workflow
8.2.6.3.3 Market size and forecast, by Therapeutic area
8.2.6.3.4 Market size and forecast, by Drug Type
8.2.6.3.5 Market size and forecast, by End User
8.3 Europe
8.3.1 Key trends and opportunities
8.3.2 Europe Market size and forecast, by Workflow
8.3.3 Europe Market size and forecast, by Therapeutic area
8.3.4 Europe Market size and forecast, by Drug Type
8.3.5 Europe Market size and forecast, by End User
8.3.6 Europe Market size and forecast, by country
8.3.6.1 Germany
8.3.6.1.1 Key market trends, growth factors and opportunities
8.3.6.1.2 Market size and forecast, by Workflow
8.3.6.1.3 Market size and forecast, by Therapeutic area
8.3.6.1.4 Market size and forecast, by Drug Type
8.3.6.1.5 Market size and forecast, by End User
8.3.6.2 France
8.3.6.2.1 Key market trends, growth factors and opportunities
8.3.6.2.2 Market size and forecast, by Workflow
8.3.6.2.3 Market size and forecast, by Therapeutic area
8.3.6.2.4 Market size and forecast, by Drug Type
8.3.6.2.5 Market size and forecast, by End User
8.3.6.3 UK
8.3.6.3.1 Key market trends, growth factors and opportunities
8.3.6.3.2 Market size and forecast, by Workflow
8.3.6.3.3 Market size and forecast, by Therapeutic area
8.3.6.3.4 Market size and forecast, by Drug Type
8.3.6.3.5 Market size and forecast, by End User
8.3.6.4 Italy
8.3.6.4.1 Key market trends, growth factors and opportunities
8.3.6.4.2 Market size and forecast, by Workflow
8.3.6.4.3 Market size and forecast, by Therapeutic area
8.3.6.4.4 Market size and forecast, by Drug Type
8.3.6.4.5 Market size and forecast, by End User
8.3.6.5 Spain
8.3.6.5.1 Key market trends, growth factors and opportunities
8.3.6.5.2 Market size and forecast, by Workflow
8.3.6.5.3 Market size and forecast, by Therapeutic area
8.3.6.5.4 Market size and forecast, by Drug Type
8.3.6.5.5 Market size and forecast, by End User
8.3.6.6 Rest of Europe
8.3.6.6.1 Key market trends, growth factors and opportunities
8.3.6.6.2 Market size and forecast, by Workflow
8.3.6.6.3 Market size and forecast, by Therapeutic area
8.3.6.6.4 Market size and forecast, by Drug Type
8.3.6.6.5 Market size and forecast, by End User
8.4 Asia-Pacific
8.4.1 Key trends and opportunities
8.4.2 Asia-Pacific Market size and forecast, by Workflow
8.4.3 Asia-Pacific Market size and forecast, by Therapeutic area
8.4.4 Asia-Pacific Market size and forecast, by Drug Type
8.4.5 Asia-Pacific Market size and forecast, by End User
8.4.6 Asia-Pacific Market size and forecast, by country
8.4.6.1 Japan
8.4.6.1.1 Key market trends, growth factors and opportunities
8.4.6.1.2 Market size and forecast, by Workflow
8.4.6.1.3 Market size and forecast, by Therapeutic area
8.4.6.1.4 Market size and forecast, by Drug Type
8.4.6.1.5 Market size and forecast, by End User
8.4.6.2 China
8.4.6.2.1 Key market trends, growth factors and opportunities
8.4.6.2.2 Market size and forecast, by Workflow
8.4.6.2.3 Market size and forecast, by Therapeutic area
8.4.6.2.4 Market size and forecast, by Drug Type
8.4.6.2.5 Market size and forecast, by End User
8.4.6.3 Australia
8.4.6.3.1 Key market trends, growth factors and opportunities
8.4.6.3.2 Market size and forecast, by Workflow
8.4.6.3.3 Market size and forecast, by Therapeutic area
8.4.6.3.4 Market size and forecast, by Drug Type
8.4.6.3.5 Market size and forecast, by End User
8.4.6.4 India
8.4.6.4.1 Key market trends, growth factors and opportunities
8.4.6.4.2 Market size and forecast, by Workflow
8.4.6.4.3 Market size and forecast, by Therapeutic area
8.4.6.4.4 Market size and forecast, by Drug Type
8.4.6.4.5 Market size and forecast, by End User
8.4.6.5 South Korea
8.4.6.5.1 Key market trends, growth factors and opportunities
8.4.6.5.2 Market size and forecast, by Workflow
8.4.6.5.3 Market size and forecast, by Therapeutic area
8.4.6.5.4 Market size and forecast, by Drug Type
8.4.6.5.5 Market size and forecast, by End User
8.4.6.6 Rest of Asia-Pacific
8.4.6.6.1 Key market trends, growth factors and opportunities
8.4.6.6.2 Market size and forecast, by Workflow
8.4.6.6.3 Market size and forecast, by Therapeutic area
8.4.6.6.4 Market size and forecast, by Drug Type
8.4.6.6.5 Market size and forecast, by End User
8.5 LAMEA
8.5.1 Key trends and opportunities
8.5.2 LAMEA Market size and forecast, by Workflow
8.5.3 LAMEA Market size and forecast, by Therapeutic area
8.5.4 LAMEA Market size and forecast, by Drug Type
8.5.5 LAMEA Market size and forecast, by End User
8.5.6 LAMEA Market size and forecast, by country
8.5.6.1 Brazil
8.5.6.1.1 Key market trends, growth factors and opportunities
8.5.6.1.2 Market size and forecast, by Workflow
8.5.6.1.3 Market size and forecast, by Therapeutic area
8.5.6.1.4 Market size and forecast, by Drug Type
8.5.6.1.5 Market size and forecast, by End User
8.5.6.2 Saudi Arabia
8.5.6.2.1 Key market trends, growth factors and opportunities
8.5.6.2.2 Market size and forecast, by Workflow
8.5.6.2.3 Market size and forecast, by Therapeutic area
8.5.6.2.4 Market size and forecast, by Drug Type
8.5.6.2.5 Market size and forecast, by End User
8.5.6.3 South Africa
8.5.6.3.1 Key market trends, growth factors and opportunities
8.5.6.3.2 Market size and forecast, by Workflow
8.5.6.3.3 Market size and forecast, by Therapeutic area
8.5.6.3.4 Market size and forecast, by Drug Type
8.5.6.3.5 Market size and forecast, by End User
8.5.6.4 Rest of LAMEA
8.5.6.4.1 Key market trends, growth factors and opportunities
8.5.6.4.2 Market size and forecast, by Workflow
8.5.6.4.3 Market size and forecast, by Therapeutic area
8.5.6.4.4 Market size and forecast, by Drug Type
8.5.6.4.5 Market size and forecast, by End User
CHAPTER 9: COMPANY LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Key developments
CHAPTER 10: COMPANY PROFILES
10.1 . Charles River Laboratories,
10.1.1 Company overview
10.1.2 Company snapshot
10.1.3 Operating business segments
10.1.4 Product portfolio
10.1.5 Business performance
10.1.6 Key strategic moves and developments
10.2 Curia Global Inc
10.2.1 Company overview
10.2.2 Company snapshot
10.2.3 Operating business segments
10.2.4 Product portfolio
10.2.5 Business performance
10.2.6 Key strategic moves and developments
10.3 Dr. Reddy’s Laboratories
10.3.1 Company overview
10.3.2 Company snapshot
10.3.3 Operating business segments
10.3.4 Product portfolio
10.3.5 Business performance
10.3.6 Key strategic moves and developments
10.4 Dalton Pharma Service
10.4.1 Company overview
10.4.2 Company snapshot
10.4.3 Operating business segments
10.4.4 Product portfolio
10.4.5 Business performance
10.4.6 Key strategic moves and developments
10.5 Discover X Corporation
10.5.1 Company overview
10.5.2 Company snapshot
10.5.3 Operating business segments
10.5.4 Product portfolio
10.5.5 Business performance
10.5.6 Key strategic moves and developments
10.6 Laboratory Corporation of America Holdings
10.6.1 Company overview
10.6.2 Company snapshot
10.6.3 Operating business segments
10.6.4 Product portfolio
10.6.5 Business performance
10.6.6 Key strategic moves and developments
10.7 Merck & Co
10.7.1 Company overview
10.7.2 Company snapshot
10.7.3 Operating business segments
10.7.4 Product portfolio
10.7.5 Business performance
10.7.6 Key strategic moves and developments
10.8 Syngene International Ltd
10.8.1 Company overview
10.8.2 Company snapshot
10.8.3 Operating business segments
10.8.4 Product portfolio
10.8.5 Business performance
10.8.6 Key strategic moves and developments
10.9 Thermo Fisher Scientific, Inc.
10.9.1 Company overview
10.9.2 Company snapshot
10.9.3 Operating business segments
10.9.4 Product portfolio
10.9.5 Business performance
10.9.6 Key strategic moves and developments
10.10 TCG Life Science Pvt. Ltd
10.10.1 Company overview
10.10.2 Company snapshot
10.10.3 Operating business segments
10.10.4 Product portfolio
10.10.5 Business performance
10.10.6 Key strategic moves and developments
TABLE 1. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
TABLE 2. DRUG DISCOVERY OUTSOURCING MARKET FOR TARGET IDENTIFICATION AND SCREENING, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 3. DRUG DISCOVERY OUTSOURCING MARKET FOR TARGET IDENTIFICATION AND SCREENING, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 4. DRUG DISCOVERY OUTSOURCING MARKET FOR TARGET VALIDATION AND FUNCTIONAL INFORMATICS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 5. DRUG DISCOVERY OUTSOURCING MARKET FOR TARGET VALIDATION AND FUNCTIONAL INFORMATICS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 6. DRUG DISCOVERY OUTSOURCING MARKET FOR LEAD IDENTIFICATION AND CANDIDATE OPTIMIZATION, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 7. DRUG DISCOVERY OUTSOURCING MARKET FOR LEAD IDENTIFICATION AND CANDIDATE OPTIMIZATION, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 8. DRUG DISCOVERY OUTSOURCING MARKET FOR PRECLINICAL DEVELOPMENT, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 9. DRUG DISCOVERY OUTSOURCING MARKET FOR PRECLINICAL DEVELOPMENT, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 10. DRUG DISCOVERY OUTSOURCING MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 11. DRUG DISCOVERY OUTSOURCING MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 12. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 13. DRUG DISCOVERY OUTSOURCING MARKET FOR RESPIRATORY SYSTEM, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 14. DRUG DISCOVERY OUTSOURCING MARKET FOR RESPIRATORY SYSTEM, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 15. DRUG DISCOVERY OUTSOURCING MARKET FOR INFECTIOUS DISEASE, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 16. DRUG DISCOVERY OUTSOURCING MARKET FOR INFECTIOUS DISEASE, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 17. DRUG DISCOVERY OUTSOURCING MARKET FOR ONCOLOGY, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 18. DRUG DISCOVERY OUTSOURCING MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 19. DRUG DISCOVERY OUTSOURCING MARKET FOR IMMUNOLOGY, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 20. DRUG DISCOVERY OUTSOURCING MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 21. DRUG DISCOVERY OUTSOURCING MARKET FOR HEMATOLOGY, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 22. DRUG DISCOVERY OUTSOURCING MARKET FOR HEMATOLOGY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 23. DRUG DISCOVERY OUTSOURCING MARKET FOR CARDIOVASCULAR, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 24. DRUG DISCOVERY OUTSOURCING MARKET FOR CARDIOVASCULAR, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 25. DRUG DISCOVERY OUTSOURCING MARKET FOR CENTRAL NERVOUS SYSTEM (CNS), BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 26. DRUG DISCOVERY OUTSOURCING MARKET FOR CENTRAL NERVOUS SYSTEM (CNS), BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 27. DRUG DISCOVERY OUTSOURCING MARKET FOR GASTROINTESTINAL, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 28. DRUG DISCOVERY OUTSOURCING MARKET FOR GASTROINTESTINAL, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 29. DRUG DISCOVERY OUTSOURCING MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 30. DRUG DISCOVERY OUTSOURCING MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 31. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 32. DRUG DISCOVERY OUTSOURCING MARKET FOR SMALL MOLECULES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 33. DRUG DISCOVERY OUTSOURCING MARKET FOR SMALL MOLECULES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 34. DRUG DISCOVERY OUTSOURCING MARKET FOR LARGE MOLECULES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 35. DRUG DISCOVERY OUTSOURCING MARKET FOR LARGE MOLECULES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 36. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 37. DRUG DISCOVERY OUTSOURCING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 38. DRUG DISCOVERY OUTSOURCING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 39. DRUG DISCOVERY OUTSOURCING MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 40. DRUG DISCOVERY OUTSOURCING MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 41. DRUG DISCOVERY OUTSOURCING MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 42. DRUG DISCOVERY OUTSOURCING MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 43. DRUG DISCOVERY OUTSOURCING MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 44. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
TABLE 45. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 46. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 47. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 48. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 49. U.S. DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
TABLE 50. U.S. DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 51. U.S. DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 52. U.S. DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 53. CANADA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
TABLE 54. CANADA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 55. CANADA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 56. CANADA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 57. MEXICO DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
TABLE 58. MEXICO DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 59. MEXICO DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 60. MEXICO DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 61. EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
TABLE 62. EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 63. EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 64. EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 65. EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 66. GERMANY DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
TABLE 67. GERMANY DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 68. GERMANY DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 69. GERMANY DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 70. FRANCE DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
TABLE 71. FRANCE DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 72. FRANCE DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 73. FRANCE DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 74. UK DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
TABLE 75. UK DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 76. UK DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 77. UK DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 78. ITALY DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
TABLE 79. ITALY DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 80. ITALY DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 81. ITALY DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 82. SPAIN DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
TABLE 83. SPAIN DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 84. SPAIN DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 85. SPAIN DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 86. REST OF EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
TABLE 87. REST OF EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 88. REST OF EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 89. REST OF EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 90. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
TABLE 91. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 92. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 93. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 94. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 95. JAPAN DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
TABLE 96. JAPAN DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 97. JAPAN DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 98. JAPAN DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 99. CHINA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
TABLE 100. CHINA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 101. CHINA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 102. CHINA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 103. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
TABLE 104. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 105. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 106. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 107. INDIA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
TABLE 108. INDIA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 109. INDIA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 110. INDIA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 111. SOUTH KOREA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
TABLE 112. SOUTH KOREA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 113. SOUTH KOREA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 114. SOUTH KOREA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 115. REST OF ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
TABLE 116. REST OF ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 117. REST OF ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 118. REST OF ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 119. LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
TABLE 120. LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 121. LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 122. LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 123. LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 124. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
TABLE 125. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 126. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 127. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 128. SAUDI ARABIA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
TABLE 129. SAUDI ARABIA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 130. SAUDI ARABIA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 131. SAUDI ARABIA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 132. SOUTH AFRICA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
TABLE 133. SOUTH AFRICA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 134. SOUTH AFRICA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 135. SOUTH AFRICA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 136. REST OF LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
TABLE 137. REST OF LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 138. REST OF LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 139. REST OF LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 140.. CHARLES RIVER LABORATORIES,: COMPANY SNAPSHOT
TABLE 141.. CHARLES RIVER LABORATORIES,: OPERATING SEGMENTS
TABLE 142.. CHARLES RIVER LABORATORIES,: PRODUCT PORTFOLIO
TABLE 143.. CHARLES RIVER LABORATORIES,: NET SALES
TABLE 144.. CHARLES RIVER LABORATORIES,: KEY STRATERGIES
TABLE 145.CURIA GLOBAL INC: COMPANY SNAPSHOT
TABLE 146.CURIA GLOBAL INC: OPERATING SEGMENTS
TABLE 147.CURIA GLOBAL INC: PRODUCT PORTFOLIO
TABLE 148.CURIA GLOBAL INC: NET SALES
TABLE 149.CURIA GLOBAL INC: KEY STRATERGIES
TABLE 150.DR. REDDY'S LABORATORIES: COMPANY SNAPSHOT
TABLE 151.DR. REDDY'S LABORATORIES: OPERATING SEGMENTS
TABLE 152.DR. REDDY'S LABORATORIES: PRODUCT PORTFOLIO
TABLE 153.DR. REDDY'S LABORATORIES: NET SALES
TABLE 154.DR. REDDY'S LABORATORIES: KEY STRATERGIES
TABLE 155.DALTON PHARMA SERVICE: COMPANY SNAPSHOT
TABLE 156.DALTON PHARMA SERVICE: OPERATING SEGMENTS
TABLE 157.DALTON PHARMA SERVICE: PRODUCT PORTFOLIO
TABLE 158.DALTON PHARMA SERVICE: NET SALES
TABLE 159.DALTON PHARMA SERVICE: KEY STRATERGIES
TABLE 160.DISCOVER X CORPORATION: COMPANY SNAPSHOT
TABLE 161.DISCOVER X CORPORATION: OPERATING SEGMENTS
TABLE 162.DISCOVER X CORPORATION: PRODUCT PORTFOLIO
TABLE 163.DISCOVER X CORPORATION: NET SALES
TABLE 164.DISCOVER X CORPORATION: KEY STRATERGIES
TABLE 165.LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT
TABLE 166.LABORATORY CORPORATION OF AMERICA HOLDINGS: OPERATING SEGMENTS
TABLE 167.LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT PORTFOLIO
TABLE 168.LABORATORY CORPORATION OF AMERICA HOLDINGS: NET SALES
TABLE 169.LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY STRATERGIES
TABLE 170.MERCK & CO: COMPANY SNAPSHOT
TABLE 171.MERCK & CO: OPERATING SEGMENTS
TABLE 172.MERCK & CO: PRODUCT PORTFOLIO
TABLE 173.MERCK & CO: NET SALES
TABLE 174.MERCK & CO: KEY STRATERGIES
TABLE 175.SYNGENE INTERNATIONAL LTD: COMPANY SNAPSHOT
TABLE 176.SYNGENE INTERNATIONAL LTD: OPERATING SEGMENTS
TABLE 177.SYNGENE INTERNATIONAL LTD: PRODUCT PORTFOLIO
TABLE 178.SYNGENE INTERNATIONAL LTD: NET SALES
TABLE 179.SYNGENE INTERNATIONAL LTD: KEY STRATERGIES
TABLE 180.THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
TABLE 181.THERMO FISHER SCIENTIFIC, INC.: OPERATING SEGMENTS
TABLE 182.THERMO FISHER SCIENTIFIC, INC.: PRODUCT PORTFOLIO
TABLE 183.THERMO FISHER SCIENTIFIC, INC.: NET SALES
TABLE 184.THERMO FISHER SCIENTIFIC, INC.: KEY STRATERGIES
TABLE 185.TCG LIFE SCIENCE PVT. LTD: COMPANY SNAPSHOT
TABLE 186.TCG LIFE SCIENCE PVT. LTD: OPERATING SEGMENTS
TABLE 187.TCG LIFE SCIENCE PVT. LTD: PRODUCT PORTFOLIO
TABLE 188.TCG LIFE SCIENCE PVT. LTD: NET SALES
TABLE 189.TCG LIFE SCIENCE PVT. LTD: KEY STRATERGIES
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
